Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03524950
Other study ID # D to stress study of pituitrin
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date June 1, 2018
Est. completion date December 31, 2019

Study information

Verified date May 2018
Source Beijing Anzhen Hospital
Contact Xia Cao, M.D.Candidate
Phone +86-13811239739
Email 13811239739@139.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is about the effect of dexmedetomidine to the stress of pituitrin in laparoscopic hysteromyoma surgery. It is well known that pituitrin has been widespread used in the laparoscopic hysteromyoma surgery. Pituitrin includes oxytocin and vasopressin. Vasopressin increase body stress reaction through hypothalamic pituitary adrenal(HPA) axis. The HPA axis has has main role to the body stress reaction. Dexmedetomidine can inhibit the stress responses mediated by the sympathetic nervous system. Therefore,the effect of dexmedetomidine to the stress of pituitrin in laparoscopic hysteromyoma surgery is worth to be studied.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria:

Surgery will be scheduled as first case in the morning at 9 Am. On arrival to the operation room, intravenous access will be achieved with venous cannula under local anesthesia with 2% lidocaine. Monitoring consisted of 5 lead electrocardiography, pulse oximeter, noninvasive blood pressure, end tidal carbon dioxide, and bispectral index.

Exclusion Criteria:

Diabetic,chronic hypertension,patients on drugs such as beta blockers or calcium channel blockers,pregnant or lactating women, patients with abnormal serum creatinine and blood urea nitrogen, and patients with a history of allergy to drugs particularly a2 agonists.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexmedetomidine
Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1µg/Kg10minutes as loading dose, followed by 0.7µg/Kg/h for maintenance.Group C add dexmedetomidine 0.7µg/Kg10minutes as loading dose, followed by 0.5µg/Kg/h for maintenance.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Beijing Anzhen Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary acth adrenocorticotropic hormone the acth before using pituitrin 5 minutes
Primary acth adrenocorticotropic hormone the acth after using pituitrin 20 minutes
Primary acth adrenocorticotropic hormone the acth after using pituitrin 120 minutes
See also
  Status Clinical Trial Phase
Completed NCT03251677 - Total Laparoscopic Hysterectomy vs Minilap Hysterectomy N/A
Not yet recruiting NCT05884658 - Hysterectomy by Transvaginal Natural Orifice Transluminal Endoscopic Surgery Versus or Laparoscopic Hysterectomy N/A
Completed NCT03193177 - A Retrospective and Prospective Cohort Study of the 21-day Fasting-like Diet in Patients With Metabolic and Autoimmune Diseases